Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863916 | 1.00 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL15070576 | 1.00 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17359383 | 1.00 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17458663 | 1.00 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17359385 | 0.98 | POLG (0.47) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17357643 | 0.98 | POLG (0.47) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17863952 | 0.92 | POLG (0.50) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17861901 | 0.92 | POLG (0.50) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL15070639 | 0.92 | POLG (0.50) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL16374023 | 0.92 | POLG (0.50) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | claimed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | claimed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | claimed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9073960-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| WO-2014209979-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2013142525-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013096679-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | POLG 832/4885P2RY2 3628/4885P2RY4 2708/4885 |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | POLG 832/4885P2RY2 3628/4885P2RY4 2708/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLG 506/4885P2RY2 250/4885P2RY4 129/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | POLG 506/4885P2RY2 250/4885P2RY4 129/4885 |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | POLG 3925/4885P2RY2 3100/4885P2RY4 2383/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLG 1008/4885P2RY2 127/4885P2RY4 58/4885 |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLG 506/4885P2RY2 250/4885P2RY4 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.